메디톡스는 연매출 400억원 이상을 기록했던 주력제품 '메디톡신'이 지난달 17일 식약처의 판매, 사용중지 명령을 받으며 창사 이래 가장 큰 위기를 맞았다.
Medytox's flagship product Medytoxin, which recorded more than 40 billion won in annual sales, faced its biggest crisis since its foundation when it was ordered to stop selling and using the product by the Ministry of Food and Drug Safety on the 17th of last month.